• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

FENOFIBRATE Drug Record

  • Summary
  • Interactions
  • Claims
  • FENOFIBRATE chembl:CHEMBL672 Approved

    Alternate Names:

    FENOGLIDE
    NSC-281319
    FENOFIBRATE
    LIPANTIL MICRO 200
    LIPANTIL MICRO 67
    TRICOR
    TRIGLIDE
    LIPOFEN
    ANTARA
    LIPANTIL MICRO 267
    LIPIDIL
    LIPANTIL
    SUPRALIP 160
    FENOGAL
    TRICOR (TN)
    TRICOR®
    FENOFIBRATO
    ABT-335
    ISOPROPYL 2-(4-(4-CHLOROBENZOYL)PHENOXY)-2-METHYLPROPIONATE
    SUPRALIP®
    2-(4-(4-CHLOROBENZOYL)PHENOXY)-2-METHYLPROPANOIC ACID 1-METHYLETHYL ESTER
    FENOFIBRATUM
    FINOFIBRATE
    LIPANTIL (TN)
    PROCETOFEN
    FNF
    ISOPROPYL (4'-(P-CHLOROBENZOYL)-2-PHENOXY-2-METHYL)PROPIONATE
    LIPANTIL®
    rxcui:221100
    rxcui:8703
    chemidplus:49562-28-9
    pubchem.compound:3339
    chembl:CHEMBL672
    drugbank:01039

    Drug Info:

    FDA Approval not approved
    Drug Indications anticholesterolaemic agent
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antidyslipidaemic agent
    Drug Class antilipemic agents
    Year of Approval 1993
    (4 More Sources)

    Publications:

    Dana et al., 2001, Peroxisome proliferator-activated receptor subtype-specific regulation of hepatic and peripheral gene expression in the Zucker diabetic fatty rat., Metab. Clin. Exp.
    Bouly et al., 2001, Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate., J. Biol. Chem.
    Guerre-Millo et al., 2000, Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity., J. Biol. Chem.
    Clavey et al., 1999, Cell culture conditions determine apolipoprotein CIII secretion and regulation by fibrates in human hepatoma HepG2 cells., Cell. Physiol. Biochem.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Casas et al., 2000, New molecular aspects of regulation of mitochondrial activity by fenofibrate and fasting., FEBS Lett.
    Chaput et al., 2000, Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight., Biochem. Biophys. Res. Commun.
    Foucher C et al., 2004, Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes., Pharmacogenetics
    Blann et al., 2001, Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate., Am. J. Cardiol.
    Chien KL et al., 2009, Common sequence variant in lipoprotein lipase gene conferring triglyceride response to fibrate treatment., Pharmacogenomics
    Yamazaki et al., 2005, Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport., Xenobiotica
    Brisson D et al., 2002, Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients., Pharmacogenetics
    Brouillette C et al., 2004, Effect of liver fatty acid binding protein (FABP) T94A missense mutation on plasma lipoprotein responsiveness to treatment with fenofibrate., J Hum Genet
    Hiuge et al., 2007, Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level., Arterioscler. Thromb. Vasc. Biol.
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    MacDonald ML et al., 2006, Identifying off-target effects and hidden phenotypes of drugs in human cells., Nat Chem Biol
    Aslibekyan S et al., 2012, Variants identified in a GWAS meta-analysis for blood lipids are associated with the lipid response to fenofibrate., PLoS One
    Watts et al., 2003, Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome., Diabetes
    Liu Y et al., 2009, Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network study., Pharmacogenet Genomics
    Perez-Martinez P et al., 2009, Association between glucokinase regulatory protein (GCKR) and apolipoprotein A5 (APOA5) gene polymorphisms and triacylglycerol concentrations in fasting, postprandial, and fenofibrate-treated states., Am J Clin Nutr
    Lai CQ et al., 2007, Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study., Arterioscler Thromb Vasc Biol
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
    Potaczek DP et al., 2006, Interleukin-6 -174 G/C promoter polymorphism and effects of fenofibrate and simvastatin on inflammatory markers in hypercholesterolemic patients., Blood Coagul Fibrinolysis
    Wang et al., 2003, Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles., Atherosclerosis
    Sebestjen et al., 2004, Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors., Thromb. Haemost.
  • FENOFIBRATE   APOA5

    Interaction Score: 2.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19057464 19056598 17431185


    Sources:
    PharmGKB

  • FENOFIBRATE   FABP1

    Interaction Score: 1.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15249972


    Sources:
    PharmGKB

  • FENOFIBRATE   ADIPOQ

    Interaction Score: 0.85

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17194889


    Sources:
    NCI

  • FENOFIBRATE   APOA1

    Interaction Score: 0.8

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23119086 19207029


    Sources:
    PharmGKB

  • FENOFIBRATE   SCARB1

    Interaction Score: 0.71

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • FENOFIBRATE   CRP

    Interaction Score: 0.71

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • FENOFIBRATE   CFL1

    Interaction Score: 0.53

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16680159


    Sources:
    DTC

  • FENOFIBRATE   PPARA

    Interaction Score: 0.49

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction Peroxisome proliferator-activated receptor alpha agonist
    Direct Interaction yes
    Trial Name ABT-335, choline fenofibrate,TriLipix

    PMIDs:
    11474486 11342537 10828060 10494028 11752352 11018525 10799317 15608561


    Sources:
    TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

  • FENOFIBRATE   TFPI

    Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15543343


    Sources:
    NCI

  • FENOFIBRATE   CD40LG

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14612213


    Sources:
    NCI

  • FENOFIBRATE   APOB

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12606523


    Sources:
    NCI PharmGKB

  • FENOFIBRATE   ABCA1

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • FENOFIBRATE   APOE

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12042669


    Sources:
    PharmGKB

  • FENOFIBRATE   LPL

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19207029


    Sources:
    PharmGKB

  • FENOFIBRATE   IL6

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16607077


    Sources:
    PharmGKB

  • FENOFIBRATE   HLA-A

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • FENOFIBRATE   SLCO1B1

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16316932


    Sources:
    NCI PharmGKB

  • FENOFIBRATE   VEGFA

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11356390


    Sources:
    NCI

  • FENOFIBRATE   JUN

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16680159


    Sources:
    DTC

  • FENOFIBRATE   CDK1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16680159


    Sources:
    DTC

  • FENOFIBRATE   CYP3A5

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • FENOFIBRATE   ABCB1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16316932


    Sources:
    NCI

  • FENOFIBRATE   TP53

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16680159


    Sources:
    DTC

  • FENOFIBRATE   CYP2C9

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • FENOFIBRATE   KCNH2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • FENOFIBRATE   CYP3A4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • FENOFIBRATE   CYP2C19

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • FENOFIBRATE   CYP1A2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • FENOFIBRATE   AR

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: FENOFIBRATE

    • Version: 01-August-2011

    Alternate Names:
    FENOFIBRATE Primary Drug Name

    Drug Info:
    Year of Approval 1993
    Drug Class antilipemic agents

    Publications:

  • TdgClinicalTrial: FENOFIBRATE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antidyslipidaemic agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • NCI: FENOFIBRATE

    • Version: 14-September-2017

    Alternate Names:
    C29047 NCI drug code

    Drug Info:

    Publications:
    Yamazaki et al., 2005, Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport., Xenobiotica
    Wang et al., 2003, Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles., Atherosclerosis
    Sebestjen et al., 2004, Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors., Thromb. Haemost.

  • DTC: FENOFIBRATE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL672 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    MacDonald ML et al., 2006, Identifying off-target effects and hidden phenotypes of drugs in human cells., Nat Chem Biol

  • PharmGKB: fenofibrate

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Brisson D et al., 2002, Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients., Pharmacogenetics
    Lai CQ et al., 2007, Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study., Arterioscler Thromb Vasc Biol
    Liu Y et al., 2009, Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network study., Pharmacogenet Genomics

  • TTD: Fenofibrate

    • Version: 2020.06.01

    Alternate Names:
    D07XGR TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL672

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL672

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21